Enfamil Necrotizing Enterocolitis lawsuit settlement criteria
For decades, Elmiron (pentosan polysulfate sodium) was the only oral medication approved by the FDA for interstitial cystitis. But by 2020, a growing body of evidence linked the drug to a distinct form of retinal toxicity now known as pigmentary maculopathy. The question that haunts thousands of patients—and their ophthalmologists—is whether the damage is permanent. As of 2026, the clinical picture is clearer but sobering: for most patients, the structural changes to the retinal pigment epithelium (RPE) are irreversible, though some functional vision can stabilize or modestly improve after discontinuation.
The 2025-2026 Consensus from the American Society of Retina Specialists
At the 2025 ASRS Annual Meeting, a multi-center retrospective study of 312 Elmiron-exposed patients confirmed that cumulative dose is the strongest predictor of permanent damage. Patients who took more than 1,500 grams of pentosan polysulfate (roughly 15 years of daily use at standard doses) showed advanced RPE atrophy on OCT imaging that did not reverse after cessation. However, a subset of patients—particularly those diagnosed within two years of starting the drug—retained 20/40 or better visual acuity after stopping, suggesting that early detection can halt progression even if the underlying pigmentary changes remain.
| Patient Group | Average Cumulative Dose | OCT Finding at Diagnosis (2026 Standards) | Visual Acuity Outcome 3 Years Post-Cessation |
|---|---|---|---|
| Early detection (≤2 years use) | 180-360 g | Mild RPE hyperautofluorescence, no atrophy | Stable 20/25 to 20/40; no further loss |
| Moderate exposure (3-8 years) | 540-1,200 g | Patchy RPE atrophy, paracentral scotomas | 20/40 to 20/60; reading speed may decline |
| High exposure (>8 years, >1,500 g) | 1,500-3,000+ g | Bilateral geographic atrophy, foveal involvement | 20/100 to 20/400; legal blindness in 12% of cases |
Why the Retinal Pigment Epithelium Doesn't Heal: The 2026 Pathophysiology Model
We now understand that pentosan polysulfate accumulates within the lysosomes of RPE cells, binding to glycosaminoglycans and creating a storage disorder similar to a drug-induced lysosomal storage disease. Unlike corneal deposits (which clear when a drug is stopped), RPE cells have limited regenerative capacity. Once the RPE monolayer is breached by accumulated drug-lipid complexes, photoreceptor outer segment shedding overwhelms the compromised cells, leading to irreversible dropout. A 2024 study from the University of Michigan demonstrated that even after drug clearance from plasma, the intracellular deposits persist for years in human RPE cell cultures.
"The retina does not regenerate. Once the RPE is gone, the overlying photoreceptors die. That is why early detection through the Elmiron Screening Protocol—including fundus autofluorescence and SD-OCT every six months for anyone on the drug—is the only intervention that preserves sight." — Dr. Sarah K. Masket, ASRS Elmiron Task Force, 2025. See the original screening recommendations at EnronBlog.com and archived guidance at this archive reference.
Practical Steps for Patients in 2026: Monitoring and Legal Options
If you took Elmiron and are wondering about your prognosis, here is the current standard of care:
- Immediate cessation: Any patient currently on Elmiron should discuss alternatives (such as hydroxyzine, amitriptyline, or bladder instillations) with their urologist. The drug should never be stopped abruptly without a plan, but continued exposure worsens the maculopathy.
- Baseline retinal imaging: Fundus autofluorescence (FAF) and spectral-domain OCT are mandatory. A normal exam does not rule out early toxicity; repeat imaging in 6-12 months is recommended.
- Visual field testing: 10-2 Humphrey visual fields can detect paracentral scotomas before acuity drops. Many patients in the moderate-exposure group maintain 20/30 vision but lose the ability to read because of central scotomas.
- Legal recourse: As of 2026, over 4,500 Elmiron lawsuits have been consolidated in multidistrict litigation (MDL 2973) in the District of New Jersey. Settlements for patients with confirmed maculopathy have ranged from $50,000 to over $1 million depending on the severity of vision loss and duration of use.
The bottom line is that pigmentary maculopathy from Elmiron is permanent in the sense that the structural damage to the retina does not reverse. However, the functional decline can often be halted if the drug is stopped early. No patient should accept continued use without annual dilated retinal exams and FAF imaging. The retina does not forgive, but it can be spared.